GlassScriptPhysician profile
Chaz Davis
NPI 1932672011
$3,191.84
in general payments reported to CMS, 2019-2025
37 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $28.39 · 2024: $2,717 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.45 |
| Education | $356.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.66 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $363.55 | 2024-2025 | Enhertu, Imfinzi, Calquence |
| Janssen Biotech, INC. | $353.68 | 2024 | Erleada, Akeega, Darzalex |
| Merck Sharp & Dohme LLC | $258.83 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $226.36 | 2024 | |
| Eisai INC. | $168.88 | 2024 | |
| Incyte Corporation | $161.23 | 2024 | Jakafi, Monjuvi |
| Genentech USA, INC. | $138.65 | 2024-2025 | Tecentriq, Phesgo, Alecensa |
| Lilly USA, LLC | $112.96 | 2024 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $109.44 | 2024 | Iclusig, Fruzaqla |
| Astellas Pharma US INC | $92.99 | 2025 | |
| Daiichi Sankyo INC. | $91.59 | 2024 | Enhertu, Injectafer |
| Sobi, INC | $83.53 | 2024 | |
| Genmab U.S., INC. | $72.60 | 2024 | Epkinly, Tivdak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.53 | 2021-2024 | Gilotrif |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaz Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.